Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 4/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.36 |
| ▸ | PER2 | O15055 | 3/20 | 0.36 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845739 | 0.88 | CFTR (0.38) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL12827355 | 0.86 | HDAC10 (0.39) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL20808191 | 0.84 | NR1I2 (0.34) | NR1I2CFTRCACNA1BPER2CRY1 | |
| SCHEMBL15096107 | 0.75 | NR1I2 (0.43) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL12745363 | 0.75 | NR1I2 (0.43) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL12745368 | 0.74 | NR1I2 (0.42) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL21341336 | 0.65 | KCNH2 (0.38) | NR1I2HDAC10HDAC6CFTRDNMT1 | |
| SCHEMBL12745353 | 0.64 | KCNH2 (0.49) | NR1I2 | |
| SCHEMBL14845720 | 0.63 | CFTR (0.42) | NR1I2HDAC10HDAC6CFTRCACNA1B | |
| SCHEMBL16449989 | 0.62 | KCNH2 (0.41) | NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-9974781-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974781-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-22 | — | — | US | disclosed |
| US-20150174098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150094304-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMA (US) | 2015-04-02 | — | — | US | disclosed |
| US-8952050-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623905-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8575209-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vextex Pharmaceuticals Incorporated (US) | 2013-07-11 | — | — | US | disclosed |
| US-8415387-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110060024-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20150094304-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | NR1I2 791/4885HDAC10 3186/4885HDAC6 1051/4885 |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
| US-20110060024-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885HDAC10 2755/4885HDAC6 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.